F2 and Cirrhosis: Even in the presence of noticeably abnormal platelet counts and/or prothrombin times, prohemostatic therapy is not the first line of treatment for bleeding patients with cirrhosis because these patients typically have adequate hemostatic competence and because bleeding complications may not be related to hemostatic failure.